Professor Giampaolo Bianchini shares his insights on the DESTINY-Breast12 study.

Video: https://medicaldigest.org/scientific-contents/interview:substantial-and-durable-overall-and-intracranial-activity-trastuzumab-deruxtecan-previously-treated-her2-positive-mbc-including-large-cohort-patients-brain-metastases

Professor Petros Grivas shares his insights on the NIAGARA study.

Video: https://medicaldigest.org/scientific-contents/interview:randomized-phase-3-trial-neoadjuvant-durvalumab-plus-chemotherapy-followed-radical-cystectomy-and-adjuvant-durvalumab-muscle-invasive-bladder-cancer

Professor Petros Grivas shares his insights on the AMBASSADOR study.

Video: https://medicaldigest.org/scientific-contents/interview:adjuvant-pembrolizumab-prolongs-dfs-among-patients-high-risk-muscle-invasive-urothelial-carcinoma

Professor Yelena Janjigian shares his thoughts on biomarker selected strategies and immunotherapy change the landscape of upper GI tumor treatment from ESMO2024.

Video: https://medicaldigest.org/scientific-contents/interview:biomarker-selected-strategies-and-immunotherapy-change-landscape-upper-gi-tumor-treatment

Professor Dirk Arnold shares his thoughts on lower gastrointestinal news from ESMO2024.

Video: https://medicaldigest.org/scientific-contents/interview:rise-cancer-young-adults-lower-gi-news-esmo2024

Professor Federica Di Nicolantonio shares his thoughts on the Rome and GigaPath trials and the importance of moving towards molecular and AI-driven oncology.

Video: https://medicaldigest.org/scientific-contents/interview:eyes-future-moving-towards-molecular-and-ai-driven-oncology

Professor Petra Tesarova shares his thoughts on CDK 4-6 inhibitors in early breast cancer.

Video: https://medicaldigest.org/scientific-contents/interview:incorporating-novel-treatment-insights-er-early-bc-patients-report-esmo2024

Professor Davide Melisi shares his thoughts on novel targeted therapies for pancreatic cancer.

Video: https://medicaldigest.org/scientific-contents/interview:novel-targeted-therapies-pancreatic-cancer

Professor David Sebag-Montefiore shares his thoughts on systemic therapy for organ preservation and the findings from the NO-CUT trial were presented at the ESMO Congress 2024. The study explored the efficacy of more aggressive initial treatment known as total neoadjuvant therapy followed by non-operative management in patients with mismatch repair proficient locally advanced rectal cancer.

Video: https://medicaldigest.org/scientific-contents/interview:systemic-therapy-organ-preservation

Professor Andrea Botticelli presented the Rome trial results at ESMO 24 Presidential Session. Patients with advanced cancers receiving tumor-agnostic treatments based on the recommendations of a molecular tumor board had significantly better response rates and lived longer without the disease progressing than those receiving the standard of care in the ROME trial.

Video: https://medicaldigest.org/scientific-contents/interview:rome-trial-histology-target-road-personalize-targeted-therapy-and-immunotherapy